In a recent article on published on the Pharma Marketing Blog by John Mack the author, also known as @pharmaguy discussed the subject of health-related mobile applications and the mobile optimization of online content. To decide which one is more important to pharma is not the main task at hand. Our first and most important concern should not be whether one or the other could achieve a higher ROI. Simply because even if it turns out that online content optimal for mobile consumption brings higher ROI, pharma cannot deny the increasing popularity of health apps and the potential they provide. The same way mobile optimization cannot be ignored if health applications turn out to be the holy grail of patient engagement.
The article mentioned above refers to the Mobile Health 2012 survey published by the Pew Internet and American Life Project which showed that “half of smartphone owners use their devices to get health information and one-fifth of smartphone owners have health apps.” The study also pointed out that only around 9% of US adults have health applications on their phones. And @pharmaguy is right, this does not mean that these apps are used. How many times do we download an application and later find it impossible or even annoying to use?
Although the data about mobile health apps does not seem too promising, the percentage of smartphone owners who use their devices to access health-related information almost doubled. But does this tell us to focus exclusively on mobile optimization because that is what the current trend tells us? In my opinion this should be more of a wake up call or a warning sign that while online content has to be accessible on mobile devices, there is also a lot more to do to develop truly user-friendly health apps that users don’t just download but actually end up using as well. With only 19% of pharma websites being optimized for mobile platforms it is clear that there is a lot of unfulfilled potential in that area as well, but pharma companies are going to have to divide their efforts and make sure to achieve progress in both developing apps and optimizing online content.
Do you think pharma has the resources to conquer the challenges of the mobile era? Make sure to leave a comment below!
(Source: Pharma Marketing Blog)









The End Of Janssen’s Psoriasis 360 Facebook Page
Janssen was the first to use “post-moderated comments”, meaning that these comments were only checked – and pulled if necessary – after they were posted. This was definitely a progressive way of handling comments on Facebook, something that became mandatory after new Facebook policies were introduced in August last year.
So does this mean that pharmaceutical companies don’t have a place on Facebook? Does this mean that monitoring is a daunting task that cannot be completed? I’m sure a lot of people in the pharma industry would say so and use the closing of Psoriasis 360 as a proof to their case. But is it fair to point fingers and use a previous best practice as a bad example, or even as an excuse to stay away from social media? Can an award-winning campaign become a “failure” overnight? I surely hope the answer is no. If anything people responsible for the campaign should be praised for not letting the situation get out of hand and for addressing difficulties on time.
The end of Psoriasis 360 should not serve as a bad example, but as a great one for the proper way to handle social media risks and still keeping the main goals of social engagement and patient education in the limelight. Janssen made its announcement available on the landing page of Psoriasis 360 where they inform their fans about the reasons behind their decision. But they go a little further too, they point the patients in the right direction to get information by mentioning the websites and Twitter accounts of the Psoriasis Association, the Psoriasis Scotland Arthritis Link Volunteers and the University of Manchester Skin Research as accurate and useful resources. The company also decided to take a little time before closing down the page entirely to make sure its message gets through to patients. If anything, this process should be a best practice example of how and when to end a social media campaign.
And before anyone accuses me of being too positive and forgiving, this event should also work as a catalyst to generate more ideas to better manage the task of monitoring social platforms, the handling of comments coming from the audience and keeping alive successful campaigns while staying in line with regulations.
(Source: PMLiVE.com)
Posted by h2online on March 22, 2012
http://pharma7cee.com/2012/03/22/the-end-of-janssens-psoriasis-360-facebook-page/